About

Overview

2015

NK CELL CULTURE TECHNOLOGY R&D

  • Development of culture technology and research on product toxicity, cell number, purity, etc.
  • Research on natural substances and proteins for development of new culture techniques
  • Research and development of immune-enhancing immune cell therapy
  • NK cell culture technology research and development
2016 ~ JUN 2017

DEVELOPMENT OF NK CELL POPULATION GROWTH CULTURE METHOD

  • Jun 2017, presentation of the non-clinical results of brain tumors at the 4th Association of Regenerative Medicine Symposium held in Tokyo, Japan
  • Apr 2017, patent application for a method of mass propagation of natural killer cells (10-2017-0050837, PCT/KR2017005571)
  • Feb 2017, patent application for unmanned sterile automatic cell culture device (10-2017-0023379)
  • Dec 2016, patent application for large-scale proliferation and activation of NK cells using macrophages, etc. (10-2016-0168274, PCT/KR2016/014502)
  • Development of a high-proportion NK cell and high-dose immune cell culture method
  • Mar 2016, establishment of Imunis Biotech Co., Ltd.
JUL 2017

ENSURING COMPETITIVENESS THROUGH CLINICAL TRIALS AND ENTERING JAPANESE MARKET

  • Starting a commercial treatment business in Japan: Clinics and CPC contracts (Approval of sales permit: April)
  • Participated in the fourth R&D-oriented high-quality pharmaceutical and biological growth company IR (IPIR/Invest Fair 2017-Season IV): co-hosted by the Korea New Drug Research Association and the Korea Health Industry Development Institute
  • Nov 2017, completion of liver cancer non-clinical trials (SK-Hep1 cell, International St. Mary’s Hospital)
  • Sep 2017, transfer of patent for formulation and manufacturing method of α-lipoic acid nanoparticles with improved stability (KR10-1021619)
  • Jul 2017, signed an MOU with Japanese company D for the immune cell therapy business
  • Jul 2017, signed a technology transfer confidentiality agreement with Japanese company F
  • Jul 2017, completion of non-clinical trials of brain tumors (U87MG cell, Biotoxtech)
2018

JAPAN FDA APPROVAL

  • Recognized by Japan FDA
2019

VIETNAM CENTER

  • Opening of Vietnam Immunisbio Center with company A
MAR 2020

MALAYSIA CENTER

  • Immunisbio’s patented technology was exported completely to Malaysia
  • Located in the heart of Kuala Lumpur, specializing in NK cell immunotherapy

Mission

Our primary goal is to help patients fight pathological challenges effectively through prevention and healing.

building-icon

Malaysia Centre

Kuala Lumpur

L1-22A, United Point Mall, 10, Jalan Lang Emas, 51200 KL

 

Our Centres Worldwide

Japan

18-4 Fuyuki, Koto-ku, Tokyo 135-0041, Japan

 

Republic of Korea

B2, International St. Mary’s Hospital MTP Mall, Simgokro 100 Beongil 31, Seo-gu, Incheon, Korea